Aberdeen Group plc Sells 76,076 Shares of Amgen Inc. $AMGN

Aberdeen Group plc trimmed its position in Amgen Inc. (NASDAQ:AMGN) by 11.2% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 602,539 shares of the medical research company’s stock after selling 76,076 shares during the period. Aberdeen Group plc owned 0.11% of Amgen worth $166,825,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Cidel Asset Management Inc. increased its position in shares of Amgen by 4.3% during the 3rd quarter. Cidel Asset Management Inc. now owns 3,380 shares of the medical research company’s stock valued at $954,000 after purchasing an additional 138 shares during the last quarter. Vista Capital Partners Inc. boosted its stake in Amgen by 20.4% in the third quarter. Vista Capital Partners Inc. now owns 932 shares of the medical research company’s stock worth $263,000 after buying an additional 158 shares in the last quarter. BTC Capital Management Inc. grew its position in Amgen by 36.9% during the third quarter. BTC Capital Management Inc. now owns 11,008 shares of the medical research company’s stock valued at $3,106,000 after acquiring an additional 2,969 shares during the last quarter. Balboa Wealth Partners raised its stake in shares of Amgen by 5.0% during the third quarter. Balboa Wealth Partners now owns 1,035 shares of the medical research company’s stock worth $292,000 after acquiring an additional 49 shares in the last quarter. Finally, Pacific Sage Partners LLC raised its stake in shares of Amgen by 2.5% during the third quarter. Pacific Sage Partners LLC now owns 5,380 shares of the medical research company’s stock worth $1,518,000 after acquiring an additional 133 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: European Commission approval for Uplinza (amifampridine) for generalized myasthenia gravis expands Amgen’s labelled indications in Europe and supports incremental near-term revenue potential for the product. Amgen wins EC approval for Uplinza in gMG
• Positive Sentiment: Amgen announced an increase to its dividend to $2.52, which boosts yield and signals management confidence in cash flow — typically supportive for a large-cap, dividend-oriented stock. Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.52
• Positive Sentiment: Unusually large call-option activity (roughly 320,232 calls bought) points to short-term bullish positioning by some investors, which can amplify upside moves in the stock. (No source link provided in feed)
• Neutral Sentiment: Amgen will present at Citi’s 2026 Virtual Oncology Leadership Summit — a standard investor relations event that raises visibility on oncology programs but is not intrinsically catalytic. AMGEN TO PRESENT AT CITI’S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT
• Neutral Sentiment: Analyst notes are mixed: Argus reiterated a Buy with a $400 target while Guggenheim reaffirmed a Hold — this provides conflicting signals but keeps the stock in analysts’ focus. Here’s What Argus Research and Guggenheim Are Saying About Amgen Inc. (AMGN)
• Neutral Sentiment: Industry coverage (CNBC) on pharma’s resetting priorities — pricing, pipelines and patent cliffs — is a sector-level backdrop that could affect sentiment for large-cap drugmakers like Amgen but is not company-specific. Prices, pipelines and patent cliffs: Inside pharma’s big reset
• Neutral Sentiment: Recent entries on short interest in the data feed appear to be reporting zero shares / NaN changes (likely a reporting glitch) and do not signal a meaningful rise in short positioning. (No link provided)

Insider Buying and Selling at Amgen

In related news, SVP Nancy A. Grygiel sold 3,139 shares of Amgen stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the transaction, the senior vice president owned 7,225 shares in the company, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.76% of the stock is currently owned by insiders.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $369.19 on Friday. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $385.12. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The business has a fifty day moving average price of $337.47 and a 200-day moving average price of $313.68. The company has a market capitalization of $198.80 billion, a PE ratio of 25.94, a PEG ratio of 3.78 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion for the quarter, compared to analysts’ expectations of $9.46 billion. During the same quarter in the prior year, the company posted $5.31 earnings per share. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, equities analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be issued a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s payout ratio is presently 66.90%.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. BMO Capital Markets raised their price target on Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 3rd. Guggenheim raised their target price on shares of Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a report on Friday, February 6th. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a report on Monday, December 29th. Citigroup increased their price target on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research report on Wednesday, February 4th. Finally, Leerink Partners boosted their price objective on shares of Amgen from $305.00 to $355.00 and gave the company an “outperform” rating in a research report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $354.04.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.